ストックスクリーナーアプリを入手
1.01
0.00%
0.00
アフターアワーズ：
.99
-0.02
-1.98%
前日終値:
$1.01
開ける：
$0.98
24時間の取引高:
294.94K
Relative Volume:
0.25
時価総額：
$98.38M
収益：
-
当期純損益:
$-20.31M
株価収益率:
-3.8185
EPS:
-0.2645
ネットキャッシュフロー:
$-21.07M
1週間 パフォーマンス:
+7.41%
1か月 パフォーマンス:
-16.53%
6か月 パフォーマンス:
+39.20%
1年 パフォーマンス:
+6.33%
1日の値動き範囲:
$0.9761
$1.035
1週間の範囲:
$0.94
$1.09
52週間の値動き範囲:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.01 | 101.36M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | 開始されました | Lake Street | Buy |
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
Oncolytics names Jared Kelly as CEO - MSN
Will Oncolytics Biotech Inc. benefit from geopolitical trendsJuly 2025 Earnings & Safe Entry Momentum Stock Tips - classian.co.kr
Does Oncolytics Biotech Inc. qualify in momentum factor screeningWeekly Profit Recap & Real-Time Stock Price Movement Reports - Newser
How to build a custom watchlist for Oncolytics Biotech Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - Newser
Trend analysis for Oncolytics Biotech Inc. this weekMarket Growth Report & Safe Swing Trade Setups - Newser
Applying big data sentiment scoring on Oncolytics Biotech Inc.July 2025 Trade Ideas & Daily Chart Pattern Signal Reports - Newser
Is Oncolytics Biotech Inc. building a consolidation base2025 Institutional Moves & Real-Time Stock Movement Alerts - Newser
Will Oncolytics Biotech Inc. stock recover after recent dropTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Published on: 2025-08-19 22:03:12 - Newser
Long term hold vs stop loss in Oncolytics Biotech Inc.Market Growth Report & Fast Gain Stock Tips - Newser
Oncolytics Biotech Inc. recovery potential after sell off2025 Growth vs Value & Daily Stock Trend Reports - Newser
Oncolytics Biotech Inc. stock retracement – recovery analysis2025 Institutional Moves & Fast Gaining Stock Strategy Reports - Newser
Real time breakdown of Oncolytics Biotech Inc. stock performanceMarket Risk Summary & Daily Market Momentum Tracking - Newser
Oncolytics Biotech Inc. Flashes Rebound Signal in Oversold ConditionSwing Trade & Weekly Breakout Stock Alerts - metrotimes.co.kr
Fibonacci Retracement Aligns with Support in Oncolytics Biotech Inc.2025 Trading Volume Trends & Real-Time Chart Pattern Alerts - kangso.co.kr
Is Oncolytics Biotech Inc. currently under institutional pressureQuarterly Growth Report & Weekly Top Gainers Alerts - thegnnews.com
Key metrics from Oncolytics Biotech Inc.’s quarterly dataMarket Performance Summary & Stepwise Entry/Exit Trade Alerts - Newser
Does Oncolytics Biotech Inc. show high probability of reboundJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
MACD Cross Could Confirm Trend in Oncolytics Biotech Inc.Quarterly Profit Review & Daily Stock Trend Watchlist - beatles.ru
Oncolytics Biotech (NASDAQ:ONCY) Raised to Hold at Wall Street Zen - Defense World
Lake Street Capital Begins Coverage on Oncolytics Biotech (NASDAQ:ONCY) - Defense World
Lake Street Capital Upgrades Oncolytics Biotech (TSE:ONC) to Strong-Buy - Defense World
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - Cantech Letter
Oncolytics Biotech Inc. Price Targets Raised After ReboundJuly 2025 PreEarnings & Daily Momentum Trading Reports - newsyoung.net
Oncolytics Biotech Enters Registration-Enabling Trial for Flagship Asset Pelareorep in First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - AInvest
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 - PR Newswire UK
ONCYBiotech Stocks Rally as Oncology Market Targets $866B by 2034 - mx.advfn.com
FDA Fast-Track Cancer Treatments Drive $900B Market Growth Forecast - Baystreet.ca
Oncolytics Biotech Announces AGM Voting Results - TipRanks
Lake Street Initiates Oncolytics Biotech(ONCY.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
Oncolytics Biotech shares rise 12.79% premarket after announcing positive voting results from its Annual General Meeting. - AInvest
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - easternprogress.com
Live Chart Scan Detects Wedge Pattern in Oncolytics Biotech Inc.Buy Low Sell High Stock Watch Strategy in Focus - 선데이타임즈
Can Oncolytics Biotech Inc. reach all time highs this yearDaily High ROI Stock Ideas - newsyoung.net
Oncolytics Biotech’s Transformative Year: Advancements in mPDAC Treatment with Pelareorep - TipRanks
Oncolytics Biotech’s Strategic Advances and Regulatory Prospects Bolster Buy Rating - TipRanks
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders - MarketScreener
Is Oncolytics Biotech Inc. a turnaround storyExtreme Return Watchlist - thegnnews.com
Oncolytics Biotech announces voting results from annual meeting By Investing.com - Investing.com Canada
Oncolytics Biotech announces voting results from annual meeting - Investing.com
RBC Capital Keeps Buy Rating on Oncolytics Biotech with $3.50 Price Target - AInvest
Oncolytics Biotech(R) Announces Voluntary Delisting from the Toronto Stock Exchange - MarketScreener
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Oncolytics Biotech Advances Pelareorep with Strategic Moves - MSN
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - Eastern Progress
Oncolytics Biotech: A High-Conviction Play in the Next-Gen Immunotherapy Space - AInvest
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
1.55%
0.38%
大文字化:
|
ボリューム (24 時間):